High-grade B-Cell lymphoma with MYC and BCL6 rearrangements associated with Richter transformation of chronic lymphocytic leukemia

Thomas S Rogers\textsuperscript{a,b}, Juli-Anne Gardner\textsuperscript{a,b}, Katherine A Devitt\textsuperscript{a,b}

\textbf{How to cite:} Rogers TS, Gardner J-A, Devitt KA. High-grade B-Cell lymphoma with MYC and BCL6 rearrangements associated with Richter transformation of chronic lymphocytic leukemia. 2019 Jul-Sep;9(3):e2019090. https://doi.org/10.4322/acr.2019.090

\textbf{ABSTRACT}

Richter transformation (RT), or Richter syndrome, is defined as the transformation of chronic lymphocytic leukemia (CLL) to an aggressive B-cell lymphoma. The vast majority, up to 99\%, transform into diffuse large B-cell lymphoma (DLBCL), with a small subset (<1\%) becoming classical Hodgkin lymphoma. Approximately half of RT cases progress through a pathway involving dysregulation of C-MYC. High-grade B-cell lymphoma (HGBL) is a recent diagnostic category of aggressive B-cell lymphomas set forth in the updated 2017 WHO Classification of Hematopoietic and Lymphoid Tissues. HGBL with \textit{MYC} and \textit{BCL2} and/or \textit{BCL6} rearrangements, formerly “double-hit” and “triple-hit” lymphomas, comprise the majority of HGBL cases. Patients with HGBL have a worse prognosis than those with diffuse large B-cell lymphoma. We present a case of RT with rearrangements of \textit{MYC} and \textit{BCL6}. To our knowledge, there are no reported cases of RT with a “double-hit” lymphoma genotype.

\textbf{Keywords}

Leukemia, Lymphocytic, Chronic, B-cell; Lymphoma, Non-Hodgkin; Lymphoma, Large B-cell, Diffuse; Cytogenetics

\textbf{CASE REPORT}

A 59-year-old man with a 20-year history of CLL presented with progressive shortness of breath, weight loss, and a rapidly enlarging supraclavicular lymph node. Prior therapies included fludarabine, rituximab, bendamustine, and ibrutinib. Though the CLL was never genetically characterized by FISH studies, there was a normal karyotype 3 years previously. At presentation, he had a mild microcytic anemia (HGB 11.4 g/dL; reference range [RR], 13.8-17.3 g/dL; MCV 79 fl; RR, 81-95 fl), normal white blood cell count (WBC 5,800/mL; RR, 4,000-10,400/mL), normal absolute lymphocyte count (ALC 2,090/mL; RR, 1,090-3,300/mL), and thrombocytopenia (PLT 107,000/mL; RR, 141,000-320,000/mL). LDH was elevated at 1,850 U/L (RR, 313-618 U/L). Imaging showed a large mediastinal mass with compression of the left atrium and pulmonary arteries. An excisional biopsy of the supraclavicular lymph node showed effacement of the normal nodal architecture by sheets of intermediate to large atypical lymphocytes with irregular nuclear contours and prominent nucleoli (Figure 1A). Numerous mitotic figures were present. The proliferation index, assessed by KI-67 (MIB-1), was increased at 60-70\% (Figure 1B).

\textsuperscript{a} University of Vermont Medical Center, Department of Pathology and Laboratory Medicine. Burlington, VT, USA.

\textsuperscript{b} University of Vermont, College of Medicine. Burlington, VT, USA.
Flow cytometry of the lymph node detected a lambda-restricted clonal CD5-positive B-cell population also positive for CD20(dim) and CD23(dim), and negative for CD10 and FMC7 (Figure 2).

This immunophenotype was similar to those seen in the patient’s multiple previous specimens, including lymph nodes, bone marrow, and peripheral blood over the prior 20 years. In the current study, a significant component of large cells was seen by light scatter criteria.

Cytogenetic studies revealed an abnormal karyotype with a translocation between the long
arms of chromosomes 8 and 18, additional material on the long arm of chromosome 9, and loss of the Y chromosome in 8 cells. A normal male karyotype was identified in 2 cells. There was an insufficient number of dividing cells for a 20-cell study. Fluorescence in situ hybridization (FISH) revealed a MYC gene rearrangement in 70-80% of cells and a BCL6 gene rearrangement in 81% (Figure 3). FISH for BCL2 gene rearrangement was negative. Clonal immunoglobulin gene rearrangements were detected by molecular analysis, but were different than the previous CLL clone.

The patient was treated with 3 cycles of R-CHOP, and after 2 months imaging showed progression of disease. He was started on R-ICE and underwent stem cell transplantation with successful engraftment. The disease continued to progress with involvement of the CNS and ultimately the patient developed respiratory failure. He was placed on hospice and succumbed to his illness, roughly 9 months after the initial diagnosis of transformation.

**DISCUSSION**

HGBL comprises a group of aggressive, mature B-cell lymphomas that can be further categorized as either “High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements” or “High-grade B-cell lymphoma, NOS.” Most cases belong in the former category, and were previously referred to as “double-” or “triple-hit” lymphomas (HGBL-DH). Prior to the 2016 revision to the WHO Classification of Hematopoietic and Lymphoid Tissues, these malignancies were classified as “B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.” These lymphomas typically occur in elderly patients and present at an advanced stage. About half have morphologic features typical of diffuse large B-cell lymphoma (DLBCL), while the other half have either morphologic features typical of Burkitt lymphoma or overlapping features of both. Thus, it is now recommended to do cytogenetic or molecular studies on all DLBCL, NOS cases to look for abnormalities of MYC, BCL2, and BCL6.

Within HGBL-DH, which by definition have a MYC rearrangement, BCL2 rearrangements are much more common than BCL6. One study found that out of 326 HGBL-DHs, 62% had rearrangements of MYC and BCL2, 16% had MYC, BCL2 and BCL6, and 8% MYC and BCL6. It is thought that HGBL-DH with MYC/BCL2 has a poorer prognosis than those with MYC/BCL6.

Richter transformation (RT) is the development of an aggressive non-Hodgkin lymphoma in the setting of underlying chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The onset of RT is heralded by sudden clinical deterioration, a marked increase in lymphadenopathy, splenomegaly, and worsening “B” symptoms such as fever, night sweats,
and weight loss. Risk factors for the development of RT remain poorly defined. However, several clinical features have been associated with RT including elevated serum lactate dehydrogenase, progressive lymphadenopathy, “B” symptoms, monoclonal gammopathy, and extranodal involvement. Additionally, one study suggested lymph nodes >3 cm, absence of del13q14, CD38 expression and usage of IGHV4-39 as additional risk factors. Biopsy of a suspicious transformation site, in our case a rapidly enlarging lymph node, is required to establish the diagnosis.

Up to 99% of RT cases are those that result in diffuse large B-cell lymphoma (DLBCL), with a small subset (<1%) becoming classical Hodgkin lymphoma. From a molecular standpoint, RT may develop as a clone identical to the pre-existing CLL clone, evolve from a bi-clonal phenotype, or arise as an independent, secondary lymphoma. The former two scenarios likely represent a complex, multistep process leading to the replication of a malignant clone of germinal or post-germinial B-cell origin manifesting as aggressive lymphoma. The molecular profile of RT-DLBCL is vastly different than that of de novo DLBCL. One study using whole exome sequencing and copy number analysis found, on average, CLL acquires approximately 20 new genetic lesions during the transformation process including mutations of TP53, NOTCH1, INK4a/ARF, and CDKN2A/2B. About 20% of RT cases are not clonally related to the original leukemia.

Historically, RT has been associated with a dismal prognosis, with median survival reported between five to eight months from the time of diagnosis. The most significant prognostic indicator in RT is clonal relation, with cases that are clonally unrelated having a better prognosis in general (median survival 5 years vs. 8-16 months). Amplification and/or overexpression of c-MYC is associated with a particularly poor prognosis, even in the absence of translocation to an immunoglobulin locus such as IgH. The overall response rate to chemotherapeutic regimens has been shown to be 39%, with 12% demonstrating a complete response.

There have been differing study outcomes regarding the prognostic significance of HGBL-DH MYC/BCL6, with studies reporting both better and worse clinical outcomes. Nonetheless, patients with HGBL are candidates for more aggressive chemotherapy regimens given high rates of relapse and poor survival following treatment with standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). Autologous and allogeneic hematopoietic stem cell transplants have been explored as therapeutic options, showing modest benefit in patients with chemosensitive disease.

In summary, our case represents a Richter transformation to high-grade B-cell lymphoma with MYC and BCL6 rearrangements. The immunophenotype of the aggressive lymphoma was nearly identical to the pre-existing CLL; however, molecular studies did not identify a clonal relation.

REFERENCES

1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2017.

2. Copie-Bergman C. Double-hit DLBCL: should we limit FISH testing? Blood. 2018;131(18):1997-8. http://dx.doi.org/10.1182/blood-2018-03-836361. PMid:29724715.

3. Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood. 2011;117(8):2319-31. http://dx.doi.org/10.1182/blood-2010-09-297879. PMid:21119107.

4. Ye Q, Xu-Monette ZY, Tzankov A, et al. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Oncotarget. 2016;7(3):2401-16. http://dx.doi.org/10.18632/oncotarget.6262. PMid:26573234.

5. Pillai RK, Sathanoori M, Van OSS SB, Swerdlow SH. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas. Am J Surg Pathol. 2013;37(3):323-32. http://dx.doi.org/10.1097/PAS.0b013e31826cebad. PMid:23348205.

6. Robertson LE, Pugh W, O’Brien S, et al. Richter’s syndrome: a report on 39 patients. J Clin Oncol. 1993;11(10):1985-9. http://dx.doi.org/10.1200/JCO.1993.11.10.1985. PMid:8410123.

7. Rossi D, Cerri M, Capello D, et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol. 2008;142(2):202-15. http://dx.doi.org/10.1111/j.1365-2141.2008.07166.x. PMid:18492108.

8. Mao Z, Quintanilla-Martinez L, Raffeld M, et al. IgVH mutational status and clonality analysis of Richter’s transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution. Am J Surg Pathol.
Rogers TS, Gardner J-A, Devitt KA

2007;31(10):1605-14. http://dx.doi.org/10.1097/PAS.0b013e31804bda8f. PMid:17895764.

9. Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syndrome. Blood. 2018;131(25):2761-72. http://dx.doi.org/10.1182/blood-2018-01-791376. PMid:29692342.

10. Fabbi G, Khianabian H, Holmes AB, et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med. 2013;210(11):2273-88. http://dx.doi.org/10.1084/jem.20131448. PMid:24127483.

11. Tsimberidou AM, Keating MJ. Richter syndrome: biology, incidence, and therapeutic strategies. Cancer. 2005;103(2):216-28. http://dx.doi.org/10.1002/cncr.20773. PMid:15578683.

12. Liu H, Yan Q, Nuako-Bandoh B, et al. Richter transformation: clonal identity does not indicate a linear disease progression. Br J Haematol. 2012;157(1):136-9. http://dx.doi.org/10.1111/j.1365-2457.2011.08917.x. PMid:22050709.

13. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28(20):3360-5. http://dx.doi.org/10.1200/JCO.2009.26.3947. PMid:20498406.

14. Horn H, Ziepert M, Becher C, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121(12):2253-63. http://dx.doi.org/10.1182/blood-2012-06-435842. PMid:23335369.

15. Tsimberidou AM, O’Brien S, Khouri I, et al. Clinical outcomes and prognostic factors in patients with Richter’s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol. 2006;24(15):2343-51. http://dx.doi.org/10.1200/JCO.2005.05.0187. PMid:16710033.

16. Clipson A, Barrans S, Zeng N, et al. The prognosis of MYC translocation positive diffuse large B-cell lymphoma depends on the second hit. J Pathol Clin Res. 2015;1(3):125-33. http://dx.doi.org/10.1002/jpc2.10. PMid:27347428.

17. Tzankov A, Xu-Monette ZY, Gerhard M, et al. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol. 2014;27(7):958-71. http://dx.doi.org/10.1038/modpathol.2013.214. PMid:24336156.

18. Scott DW, Mottak A, Ennish D, et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol. 2015;33(26):2848-56. http://dx.doi.org/10.1200/JCO.2014.60.2383. PMid:26240231.

Author contributions: KAD came up with the idea for the report and performed the initial workup of the case. TSR, KAD and J-AG contributed to the write-up, photographs, and editing of the final manuscript.

This manuscript is in accordance with our institution’s ethics and research committee guidelines.

Conflict of interest: None

Financial support: None

Submitted on: February 26th, 2019
Accepted on: May 4th, 2019

Correspondence
Katherine A Devitt
University of Vermont Medical Center
111 Colchester Ave, Main Campus EP-1 – Burlington/VT – USA
Zip code: 05401
Phone: 1 (802) 847-8372
Katherine.Devitt@uvmhealth.org